Biohaven Ltd. Files Definitive Proxy Statement

TL;DR

<b>Biohaven Ltd. has filed its Definitive Proxy Statement for the period ending April 30, 2024.</b>

AI Summary

Biohaven Ltd. (BHVN) filed a Proxy Statement (DEF 14A) with the SEC on March 18, 2024. Biohaven Ltd. filed a Definitive Proxy Statement (DEF 14A) on March 18, 2024. The filing covers the period ending April 30, 2024. The company's principal executive offices are located at 215 Church Street, New Haven, CT. Biohaven Ltd. was formerly known as Biohaven Research Ltd. until June 29, 2022. The filing indicates no fee was required for this filing.

Why It Matters

For investors and stakeholders tracking Biohaven Ltd., this filing contains several important signals. This DEF 14A filing is a standard requirement for public companies to provide shareholders with information regarding upcoming meetings, director nominations, executive compensation, and other corporate governance matters. Shareholders will use this document to make informed decisions when voting on proposals at the company's annual meeting, including the election of directors and approval of executive compensation plans.

Risk Assessment

Risk Level: low — Biohaven Ltd. shows low risk based on this filing. The filing is a routine DEF 14A, containing standard corporate governance information and no immediate financial or operational disclosures that would indicate high risk.

Analyst Insight

Review the proxy statement for details on director nominees, executive compensation, and any shareholder proposals to understand potential governance changes and management incentives.

Key Numbers

• 2024-04-30 — Reporting Period End Date (Conformed period of report)
• 2024-03-18 — Filing Date (Filed as of date)
• 2022-06-29 — Former Company Name End Date (Date of name change)

Key Players & Entities

• Biohaven Ltd. (company) — Registrant name
• 215 Church Street (location) — Business address
• New Haven (location) — City
• CT (location) — State
• 06510 (postal_code) — ZIP code
• Biohaven Research Ltd. (company) — Former company name
• 20220629 (date) — Date of name change
• 20240318 (date) — Filing date

FAQ

Industry Context

Biohaven Ltd. operates in the biopharmaceutical industry, focusing on the development and commercialization of therapies.

Regulatory Implications

As a public company, Biohaven Ltd. is subject to SEC regulations, including the requirement to file proxy statements (DEF 14A) for shareholder meetings.

What Investors Should Do

1. Review the director nominations and qualifications presented in the proxy statement.
2. Analyze the executive compensation details, including base salary, bonuses, and equity awards.
3. Examine any shareholder proposals and the company's recommendations for voting.

Key Dates

• 2024-03-18: Filing Date — Definitive Proxy Statement filed
• 2024-04-30: Reporting Period End — Period covered by the proxy statement

Year-Over-Year Comparison

This is the initial DEF 14A filing for the current reporting period, following the company's previous filings.

Key Financial Figures

• $43 billion — ith Pfizer's acquisition of Sea gen for $43 billion and Abbvie's acquisition of ImmunoGen f
• $10 billion — d Abbvie's acquisition of ImmunoGen for $10 billion representing the more sizeable transact
• $11 billion — d Merck's acquisition of Prometheus for $11 billion showing the ongoing interest in immunol
• $9 billion — large considerations paid for Cerevel ($9 billion) and Karuna Therapeutics ($14 billion)
• $14 billion — l ($9 billion) and Karuna Therapeutics ($14 billion) kept neuroscience squarely in the spot
• $16 billion — dramatically, with analysts detailing ~$16 billion in net outflows into this specific asse

Filing Documents

• bhvn-20240314.htm (DEF 14A) — 642KB
• bhvn-20240314_g1.jpg (GRAPHIC) — 20KB
• bhvn-20240314_g2.jpg (GRAPHIC) — 82KB
• bhvn-20240314_g3.jpg (GRAPHIC) — 76KB
• bhvn-20240314_g4.jpg (GRAPHIC) — 103KB
• bhvn-20240314_g5.jpg (GRAPHIC) — 104KB
• bhvn-20240314_g6.jpg (GRAPHIC) — 88KB
• bhvn-20240314_g7.jpg (GRAPHIC) — 480KB
• bhvn-20240314_g8.jpg (GRAPHIC) — 170KB
• 0001935979-24-000026.txt (&nbsp;) — 3630KB
• bhvn-20240314.xsd (EX-101.SCH) — 3KB
• bhvn-20240314_def.xml (EX-101.DEF) — 4KB
• bhvn-20240314_lab.xml (EX-101.LAB) — 5KB
• bhvn-20240314_pre.xml (EX-101.PRE) — 3KB
• bhvn-20240314_htm.xml (XML) — 62KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 21 DELINQUENT SECTION 16(a) REPORTS 23

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 23 DIRECTOR COMPENSATION 41 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS 43 TRANSACTIONS WITH RELATED PERSONS 44 HOUSEHOLDING OF PROXY MATERIALS 46 OTHER MATTERS 47 Table of Contents BIOHAVEN LTD. c/o Biohaven Pharmaceuticals, Inc. 215 Church Street New Haven, CT 06510 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF SHAREHOLDERS To Be Held on April 30, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a Notice of Internet Availability of Proxy Materials instead of paper copies of the proxy materials? Pursuant to the SEC "Notice and Access" rules, we are furnishing our proxy materials to our shareholders over the Internet instead of mailing each of our shareholders paper copies of those materials. Accordingly, we are sending our shareholders by mail a Notice of Internet Availability of Proxy Materials, which we refer to as the Notice, containing instructions on how to access our proxy materials over the Internet and how to vote. The Notice is not a ballot or proxy card and cannot be used to vote your common shares. You will not receive paper copies of the proxy materials unless you request the materials by following the instructions in the Notice or on the website referred to in the Notice. If you own common shares in more than one account—for example, in a joint account with your spouse and in your individual brokerage account—you may have received more than one Notice. To vote all of your common shares, please follow each of the separate proxy voting instructions that you received for your common shares held in each of your different accounts. We are sending the Notice to our shareholders by mail beginning on or about March 18, 2024. What information does the Notice contain? The Notice includes, among other matters: (i) the place, date and time of the 2024 Annual Meeting of Shareholders (the "annual meeting"); (ii) a brief description of the proposals to b

View Full Filing

View this DEF 14A filing on SEC EDGAR